Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age [Phase 2]

View source ↗

Summary

A Phase 2 pediatric trial evaluating the pharmacokinetics, safety and tolerability of dabigatran etexilate solution in children aged 1 to less than 2 years has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism | Phase 2 | Status: WITHDRAWN